Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis

Cytokinetics recently announced the discontinuation of Phase 3 Clinical Trial of Reldesemtiv and thanks the people with ALS, caregivers, investigators, and clinical trial staff for their participation in COURAGE-ALS.